Tango Therapeutics: Dose Escalation Ongoing in Four Clinical-Stage Precision Oncology Programs; TNG908 Phase 1/2 Clinical Data Expected in 2024 >TNGX
Tango Therapeutics: Dose Escalation Ongoing in Four Clinical-Stage Precision Oncology Programs; TNG908 Phase 1/2 Clinical Data Expected in 2024 >TNGX
Tango Therapeutics：四个临床阶段精准肿瘤学项目正在进行剂量递增；TNG908 1/2 期临床数据预计将于 2024 年发布 >TNGX
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册